Characterization of liposome-containing SPIONs conjugated with anti-CD20 developed as a novel theranostic agent for central nervous system lymphoma

被引:40
|
作者
Saesoo, S. [1 ]
Sathornsumetee, S. [1 ,3 ]
Anekwiang, P. [2 ]
Treetidnipa, C. [2 ]
Thuwajit, P. [2 ,4 ]
Bunthot, S. [1 ]
Maneeprakorn, W. [1 ]
Maurizi, L. [5 ]
Hofmann, H. [6 ]
Rungsardthong, Ruktanonchai Uracha [1 ]
Saengkrit, N. [1 ]
机构
[1] NSTDA, Natl Nanotechnol Ctr NANOTEC, Pathum Thani 12120, Thailand
[2] Mahidol Univ, Siriraj Hosp, Ctr Excellence Nanotechnol Canc Diag & Treatment, NANOTEC,Fac Med, 2 Wanglang Rd, Bangkok 10700, Thailand
[3] Mahidol Univ, Siriraj Hosp, Fac Med, Dept Med, 2 Wanglang Rd, Bangkok 10700, Thailand
[4] Mahidol Univ, Siriraj Hosp, Fac Med, Dept Immunol, 2 Wanglang Rd, Bangkok 10700, Thailand
[5] Univ Bourgogne Franche Comte, Lab Interdisciplinaire Carnot Bourgogne, UMR 6303, CNRS, BP 47870, F-21078 Dijon, France
[6] Ecole Polytech Fed Lausanne, Powder Technol Lab, CH-1015 Lausanne, Switzerland
关键词
Primary central nervous system lymphoma (PCNSL); Blood brain barrier (BBB); Brain lymphoma; Superparamagnetic iron oxide nanoparticle (SPIONs); Rituximab; Anti-CD20; Liposome; Theranostics; PRIMARY CNS LYMPHOMA; BLOOD-BRAIN-BARRIER; N-MC CELLS; COLLOIDAL STABILITY; DELIVERY-SYSTEMS; NANOPARTICLES; DEGENERATION; TRANSFERRIN; LACTOFERRIN; RITUXIMAB;
D O I
10.1016/j.colsurfb.2017.11.003
中图分类号
Q6 [生物物理学];
学科分类号
071011 ;
摘要
Despite advances in neuroscience cancer research during the past decades, the survival of cancer patients has only marginally improved and the cure remains unlikely. The blood-brain barrier (BBB) is a major obstacle protecting the entry of therapeutic agents to central nervous system, especially for primary central nervous system lymphoma (PCNSL). Thus, the use of small nanoparticle as a drug carrier may be new strategies to overcome this problem. In this study, we fabricated liposome consisting of superparamagnetic iron oxide nanoparticles (SPIONs) functionalized with anti-CD20 (Rituximab; RTX). The designed nanoparticles have a theranostic property which is not only to improve drug delivery, but also to offer diagnostic and monitoring capabilities. TEM images revealed the spherical shape of liposome with the approximately average diameters about 140-190 nm with slightly negatively charge surfaces. Super paramagnetic property of SPIONs-loaded liposomes was confirmed by VSM. Liposome colloidal could be prolonged at 4 degrees C and 25 degrees C storages. RTX conjugated liposome induced cell internalization and apoptosis effect in B-lymphoma cells. Drug targeting and therapeutic effect was investigated in BBB model. The result confirmed that liposome nanocarrier is required as a drug carrier for effectively RTX across the BBB. (C) 2017 Elsevier B.V. All rights reserved.
引用
收藏
页码:497 / 507
页数:11
相关论文
共 13 条
  • [1] Intraventricular treatment of relapsed central nervous system lymphoma with the anti-CD20 antibody rituximab
    Schulz, H
    Pels, H
    Schmidt-Wolf, I
    Zeelen, U
    Germing, U
    Engert, A
    HAEMATOLOGICA, 2004, 89 (06) : 753 - 754
  • [2] Imaging and Therapy with Rituximab Anti-CD20 Immunotherapy in an Animal Model of Central Nervous System Lymphoma
    Muldoon, Leslie L.
    Lewin, Seth J.
    Dosa, Edit
    Kraemer, Dale F.
    Pagel, Michael A.
    Doolittle, Nancy D.
    Neuwelt, Edward A.
    CLINICAL CANCER RESEARCH, 2011, 17 (08) : 2207 - 2215
  • [3] Primary central nervous system lymphoma: Current state of anti-CD20 therapy and appraisal of reported response criteria
    Siegal, Tali
    JOURNAL OF CLINICAL NEUROSCIENCE, 2014, 21 (05) : 709 - 715
  • [4] Anti-CD20 treatment and neutrophil function in central nervous system demyelinating diseases
    Balazs, Irina
    Horvath, Angela
    Heschl, Bettina
    Khalil, Michael
    Enzinger, Christian
    Stadlbauer, Vanessa
    Seifert-Held, Thomas
    JOURNAL OF NEUROIMMUNOLOGY, 2023, 381
  • [5] Complement activation in circulation and central nervous system after Rituximab (Anti-CD20) treatment of B-Cell lymphoma
    Harjunpää, A
    Wiklund, T
    Collan, J
    Janes, R
    Rosenberg, J
    Lee, D
    Grillo-López, A
    Meri, S
    LEUKEMIA & LYMPHOMA, 2001, 42 (04) : 731 - 738
  • [6] Targeting Central Nervous System B Cells in Progression of Multiple Sclerosis Is Intrathecal Anti-CD20 a Therapeutic Option?
    Fereidan-Esfahani, Mahboobeh
    Brueck, Wolfgang
    Weber, Martin S.
    JAMA NEUROLOGY, 2015, 72 (12) : 1407 - 1408
  • [7] Fatal underhanded chronic enterovirus infection associated with anti-CD20 monotherapy for central nervous system demyelinating disease
    Luciani, Lea
    Ninove, Laetitia
    Zandotti, Christine
    Chalvignac, Virginie
    Lagier, David
    Baume, Julien
    Melade, Julien
    Piorkowski, Geraldine
    Coutard, Bruno
    Lepidi, Hubert
    Pelletier, Jean
    Audoin, Bertrand
    Rico-Lamy, Audrey
    Nougairede, Antoine
    MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (02) : 320 - 323
  • [8] Characterization of a Novel Humanized Anti-CD20 Antibody with Potent Anti-Tumor Activity against Non-Hodgkin's Lymphoma
    Zhang, Haifeng
    Song, Liping
    Ye, Hongtu
    Hu, Lide
    Liang, Wenlu
    Liu, Datao
    CELLULAR PHYSIOLOGY AND BIOCHEMISTRY, 2013, 32 (03) : 645 - 654
  • [9] Systemic administration of anti-CD20 indirectly reduces B cells in the inflamed meninges in a chronic model of central nervous system autoimmunity
    Tesfagiorgis, Yodit
    Kemal, Eden A.
    Craig, Heather C.
    Parham, Kate A.
    Kerfoot, Steven M.
    JOURNAL OF NEUROIMMUNOLOGY, 2024, 387
  • [10] Fatal central nervous system lesions emerging during anti-CD20 monoclonal antibody therapy (rituximab) for a post transplantation Epstein Barr virus-linked lymphoma
    Sirvent-von Bueltzingsloewen, A
    Sirvent, N
    Morand, P
    Cassuto, JP
    MEDICAL AND PEDIATRIC ONCOLOGY, 2003, 40 (06): : 408 - 409